ChineseInvestors.com, Inc. (OTCQB: CIIX), a company in the business of providing Chinese-speaking investors with real-time market analysis, commentary, and educational services, recently announced its goals for 2017, stating that it plans to develop a CBD oil-based pharmaceutical that could help with the major problem of epilepsy in China.
The nutraceutical industry boasts a diversified playing field, and Canada-based Algae Dynamics Corp. (OTCQB: ADYNF) is taking a unique approach to this burgeoning market, focusing on the development of proprietary research and products that combine the health benefits of botanical oils derived from cannabis and algae.
Also known as Lou Gehrig’s disease, ALS is a fatal illness that attacks the nerve cells that control voluntary muscles such as those in the face, arms, legs, and others.
India Globalization Capital, Inc. (NYSE MKT: IGC) has named Craig Cheifetz, M.D., as an advisor to aid the company in its clinical trials in microbiology, immunology, neuroscience, and biotechnology.
Although legal in 28 states for medicinal use, cannabis is still considered a dangerous substance in much of the country. However, many experts now believe that cannabis is a safe alternative to pharmaceuticals for relieving symptoms related to multiple illnesses.
InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) study, which generated an article published in the European Journal of Pain (http://nnw.fm/SVF1j), sets the stage for more research into how a topically-applied drug can provide relief of chronic or acute pain without central side effects, according to Dr. Sazzad Hossain, chief scientific officer of InMed.
InMed Pharmaceuticals, Inc. (OTCQB: IMLFF), a pre-clinical stage biopharmaceutical company that specializes in the development of therapies through research and development into the pharmacology of cannabinoids and drug delivery systems, continues to get positive media coverage of ongoing operational developments, propelled by the company’s impressive leadership team.
How does a company in the mining industry successfully move toward becoming a leader in the marijuana sector, specifically cannabinoid-based pharmaceutical therapies that treat a variety of diseases and conditions?
Savvy investors should be keeping a close eye on some key developments that have taken place within the past year relating to Alzheimer’s disease, medical cannabis, and India Globalization Capital (NYSE MKT: IGC)
India Globalization Capital, Inc. (NYSE MKT: IGC), a Maryland-based company, is currently preparing four products for medical trials, including Hyalolex for the treatment of Alzheimer’s disease.
Marijuana use is currently illegal in China, but cannabis-based oils, including hemp-based CBD, are legal, giving CIIX access to a market of almost two billion potential customers in that country.
CBD has long been considered to have a broad range of medical benefits. Now, two major studies released in the last four months have scientifically validated the medicinal efficacy of CBD.
At first blush, India Globalization Capital (NYSE: IGC) would seem a curiosity clothed in an enigma. Just how does a NYSE company move from a successful mining orientation to a pioneer in the development of multiple cannabinoid-based pharmaceutical therapies to treat pain and disease?
India Globalization Capital (NYSE MKT: IGC) formerly mined and converted low-grade iron ore to high-grade ore until prices plummeted. It was then that company management made the decision that to preserve shareholder value it must change course.
With an annual growth rate of nearly 60 percent, CBD oil has become one of the fastest-growing market categories in the country. U.S.-based ChineseInvestors.com, Inc. (OTCQB: CIIX) is set to capitalize on this meteoric growth.
